This study investigated the protective effects of carvedilol, a potent antioxidant, in a rat model of tourniquet-induced ischaemia-reperfusion injury of the hind limb. Thirty rats were divided equally into three groups: the control group (group 1) was only anaesthetized, without creating an ischaemia-reperfusion injury; group 2 was submitted to ischaemia (4 h), followed by a 2-h reperfusion period; and group 3 was pre-treated with carvedilol (2 mg/kg per day) for 10 days prior to ischaemia-reperfusion. Ischaemia-reperfusion produced a significant decrease in superoxide dismutase and glutathione peroxidase activities in the liver, lungs, muscle and serum compared with control treatment, and pre-treatment with carvedilol prevented these changes. Ischaemia-reperfusion caused a significant increase in malondialdehyde and nitric oxide (NO) levels in liver, lungs, muscle (except NO) and serum compared with control treatment, and carvedilol prevented these changes. In conclusion, it might be inferred that carvedilol could be used safely to prevent oxidative injury during reperfusion following ischaemia in humans.
Da SilveiraMYoshidaWB: Ischemia and reperfusion in skeletal muscle injury mechanism and treatment perspectives. J Vasc Br2004; 3: 367–378.
3.
GrisottoPCdos SantosACCoutinho-NettoJCherriJPiccinatoCE: Indicators of oxidative injury and alterations of the cell membrane in the skeletal muscle of rats submitted to ischemia and reperfusion. J Surg Res2000; 92: 1–6.
4.
DhallaNSElmoselhiABHataTMakinoN: Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res2000; 47: 446–456.
5.
BeckerLB: New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res2004; 61: 461–470.
6.
WallJ: Antioxidants in prevention of reperfusion damage of vascular endothelium. TSMJ2000; 1: 67–71.
7.
SlaterTF: Free-radical mechanisms in tissue injury. Biochem J1984; 222: 1–15.
8.
SaijonmaaOMetsarinneKFyhrquistF: Carvedilol and its metabolites suppress endothelin-1 production in human endothelial cell culture. Blood Press1997; 6: 24–28.
9.
Guide for the Care and Use of Laboratory Animals. Institute for Laboratory Animal Research. Washington DC: The National Academies Press, 1996.
10.
NecasJBartosikovaLDrapelovaLHusekKPavlicekVKuchtickovaS: The effects of carvedilol, a beta-blocker, in experimental ischemia-reperfusion kidney injury (in Czech). Vnitr Lek1997; 43: 707–711.
CargnoniACeconiCBernocchiPBorasoAParrinelloGCurelloS: Reduction of oxidative stress by carvedilol: Role in maintenance of ischaemic myocardium viability. Cardiovasc Res2000; 47: 556–566.
IlhanAYilmazHRArmutcuFGurelAAkyolO: The protective effect of nebivolol on ischemia/reperfusion injury in rabbit spinal cord. Prog Neuropsychopharmacol Biol Psychiatry2004; 28: 1153–1160.
26.
YueTLLyskoPGBaroneFCGuJLRuffoloRRFeuersteinGZ: Carvedilol, a new antihypertensive drug with unique antioxidant activity: Potential role in cerebroprotection. Ann N Y Acad Sci1994; 738: 230–242.
27.
ChristopherTALopezBLMaXLFeuersteinGZRuffoloRRYueTL: Effects of a hydroxylated metabolite of the betaandrenoreceptor antagonist, carvedilol, on post-ischaemic splanchnic tissue injury. Br J Pharmacol1998; 123: 292–298.
28.
MaXLYueTLLopezBLBaroneFCChristopherTARuffoloRR: Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholes-terolemic rabbits. J Pharmacol Exp Ther1996; 277: 128–136.
29.
YueTLMcKennaPJRuffoloRRFeuersteinG: Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol1992; 214: 277–280.
YueTLChengHYLyskoPGMcKennaPJFeuersteinRGuJL: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther1992; 263: 92–98.
